Long-form research, revised in place. Every report is free — we ask for an email so we can tell you when the thesis changes.
Updated August 2026 · 45 min read
Four 2026 debuts that may be worth a look after their first months of trading, and three pipeline names worth preparing for before they price. Verified figures, real risks, no hype.
Updated August 2026 · 36 min read
Seven robotics and automation stocks screened on real business traction, current catalysts, valuation support, and technical strength, with the specific case for and against each one.
Updated August 2026 · 10 min read
Five NYSE- and Nasdaq-listed companies trading under $5 a share that passed our screens for size, liquidity and real revenue, with the case for and against each one.
Updated August 2026 · 35 min read
Seven NYSE and Nasdaq listed companies paying 5% to nearly 10% in cash yields, screened for payout coverage, balance sheet strength, and long dividend track records. Data as of August 2026.